{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/influenza-seasonal/diagnosis/diagnosis/","result":{"pageContext":{"chapter":{"id":"dcd79bc4-67e6-52b5-af13-ab18772e4c55","slug":"diagnosis","fullItemName":"Diagnosis","depth":2,"htmlHeader":"<!-- begin field a2bd8428-42e7-487e-b284-46f49f3a42bf --><h2>How should I diagnose seasonal influenza?</h2><!-- end field a2bd8428-42e7-487e-b284-46f49f3a42bf -->","summary":"","htmlStringContent":"<!-- begin item 71e1a5ec-3896-4e86-b184-5f1cf5c87c90 --><!-- begin field 466ebb70-aeb2-4c31-b824-e79cb3e826d7 --><ul><li><strong>The diagnosis of influenza is generally made using clinical features alone when it is known to be circulating in the community </strong>(for weekly influenza surveillance reports, visit <a data-hyperlink-id=\"5b71db95-d001-4ed3-9300-aa2a0098c692\" href=\"https://www.gov.uk/government/statistics/weekly-national-flu-reports-2018-to-2019-season\">www.gov.uk</a>). <ul><li>Diagnosis of influenza can only be confirmed by laboratory testing, although the probability that an influenza-like illness is caused by influenza is higher if influenza is known to be circulating and if a person has a high fever. </li><li>Rapid testing for influenza should be undertaken in all people with complicated influenza (although often this takes place in hospital). <ul><li>Initiation of antiviral treatment should not be delayed while awaiting laboratory confirmation. </li></ul></li><li>Laboratory testing to confirm or exclude influenza is particularly important if an individual develops symptoms despite antiviral prophylaxis, or has a persistent infection despite antiviral treatment, in order to identify the potential development of antiviral resistance. </li></ul></li><li><strong>Symptoms of influenza appear abruptly, around 2 days after exposure.</strong><ul><li><strong>Uncomplicated influenza</strong> signs and symptoms include:<ul><li>Coryza, nasal discharge.</li><li>Cough.</li><li>Fever </li><li>Gastrointestinal symptoms.</li><li>Generalised symptoms (headache, malaise, myalgia, arthralgia).</li><li>Ocular symptoms (such as photophobia, conjunctivitis, lacrimation and pain upon eye movement).</li><li>Sore throat.</li><li>No clinical features of complicated influenza. </li></ul></li><li><strong>Complicated influenza </strong>clinical features include:<strong> </strong><ul><li>Signs and symptoms that require hospital admission.</li><li>Presence of a lower respiratory tract infection (hypoxaemia, dyspnoea, lung infiltrate).</li><li>Central nervous system involvement. </li><li>Significant exacerbation of an underlying medical condition.</li></ul></li></ul></li><li><strong>Symptoms of influenza-like illness can be different in infants and children and may include:</strong><ul><li>Cervical adenopathy.</li><li>Conjunctival erythema.</li><li>Diarrhoea and vomiting — gastrointestinal symptoms are more common in children than in adults. </li><li>Fatigue. </li><li>Fever (typically 38–40°C) — children can have a higher maximum temperature. They may also present with undifferentiated fever or febrile seizures.</li><li>Hyperaemia of oropharynx. </li><li>Irritability.</li><li>Laryngotracheobronchitis (croup), bronchiolitis, or bronchitis. </li><li>Myalgia, or myositis — this can affect the calf muscles and be severe. It is a more common complication in children compared to adults.</li><li>Tachypnoea. </li></ul></li></ul><!-- end field 466ebb70-aeb2-4c31-b824-e79cb3e826d7 --><!-- end item 71e1a5ec-3896-4e86-b184-5f1cf5c87c90 -->","topic":{"id":"7143131b-dc98-5d14-aef2-f50114a27d13","topicId":"c00149e5-18ab-49c6-8576-089384091df2","topicName":"Influenza - seasonal","slug":"influenza-seasonal","lastRevised":"Last revised in August 2020","chapters":[{"id":"415ca83c-583b-5dd7-8ce7-a67a72325836","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"39d27467-6801-59da-a28b-29a9a1aa848d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7326279e-c8e9-5783-9cb0-433a2e0c5061","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ecde5124-7df2-5d70-921e-cfa13a752476","slug":"changes","fullItemName":"Changes"},{"id":"b4d67dc6-a391-5644-a3a4-89c1c0c49e3f","slug":"update","fullItemName":"Update"}]},{"id":"3b2a94ae-a366-5ff9-8a35-6f8eb63736a1","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8b66965c-fc03-5267-ac06-f0edc2bf81ea","slug":"goals","fullItemName":"Goals"},{"id":"32bc1d45-c0ea-55ed-8723-fdbf13b7196e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c5aa9558-010a-5b32-b95a-40f647ef373e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"b9c5c598-f72e-505f-b951-cbe710a6af02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d0c6ad8d-5845-5dfd-b2d0-b04bb5395c62","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"48e0bfcd-fd33-552c-b052-28533a176218","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"feb6e56c-e4f6-57f4-bbee-0876089197e0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"bc17d7e2-a53a-595c-9f57-7080c9814001","slug":"definition","fullItemName":"Definition"},{"id":"d0475ee5-11e2-5ad5-8628-4f513e50236f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a0aabed4-a912-518e-9257-8653bc7541e4","slug":"complications","fullItemName":"Complications"}]},{"id":"f81fdd28-028a-5558-92b2-90a1569692bb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"dcd79bc4-67e6-52b5-af13-ab18772e4c55","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4da6c7b5-c872-551a-aff9-100bef3041ca","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b540d9e5-48f5-5b1c-a8b1-8a37d951449f","fullItemName":"Management","slug":"management","subChapters":[{"id":"9cbc6ee5-b0da-5b46-9ce4-3704f7cf24a9","slug":"treating-influenza","fullItemName":"Scenario: Treating influenza"},{"id":"b82606d4-79c4-5b96-84cd-115c371c80b4","slug":"post-exposure-prophylaxis","fullItemName":"Scenario: Post-exposure prophylaxis"}]},{"id":"267c67be-5fb6-510f-b3f7-15ece61003d9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"418c695e-c703-5e30-9ec2-9bf2afeb6001","slug":"oseltamivir","fullItemName":"Oseltamivir"},{"id":"370b7394-2bad-5d4f-ac2a-06de67bbefea","slug":"zanamivir","fullItemName":"Zanamivir"}]},{"id":"83f51ef5-d6f9-5101-849d-c72bd5975126","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"fe85159c-da36-5171-9b52-88d8edd9ee77","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"46f280be-d769-501b-905f-789bbf2d8454","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9904923d-c7de-53aa-8253-15c9392ece2e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3790de44-d79a-5486-b053-d09c6dccc2cc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e631b66-3030-5dd0-97e7-7504198b5a14","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ab624014-37fa-5613-976c-e2ffa65a7e90","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85b4d3fc-b6de-5df4-ad98-bf9ea439e342","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f81fdd28-028a-5558-92b2-90a1569692bb","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"ced85610-7ec1-5c51-8a5a-f8ccbdd2459e","slug":"basis-for-recommendation-3fd","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 8d290312-aed4-4eed-920f-57abe99daf2a --><h3>Basis for recommendation</h3><!-- end field 8d290312-aed4-4eed-920f-57abe99daf2a -->","summary":null,"htmlStringContent":"<!-- begin item 3fd771ef-a65a-4a4c-92e4-f02b83b6aedc --><!-- begin field f739c4f4-ee56-4b3c-a2b6-cf955085116e --><p>These recommendations are based on the Public Health England (PHE) guidance <em>PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">PHE, 2019</a>], the National Institute for Health and Care Excellence (NICE) technology appraisal <em>Amantadine, oseltamivir and zanamivir for the treatment of influenza </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">NICE, 2014a</a>], the British Medical Journal (BMJ) best practice guide <em>Influenza infection</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">BMJ, 2019</a>], the Infectious Diseases Society of America (IDSA) clinical practice guideline <em>2018 Update on Diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">IDSA, 2019</a>], and expert opinion in a narrative review <em>Influenza</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/influenza-seasonal/references/\">Paules, 2017</a>].</p><!-- end field f739c4f4-ee56-4b3c-a2b6-cf955085116e --><!-- end item 3fd771ef-a65a-4a4c-92e4-f02b83b6aedc -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}